Background (1) • Rates of tobacco smoking in HIV-positive patients are very high across virtually all populations in developed countries • In the era of cART increased risk of smoking associated disease (eg cardiovascular disease, pulmonary disease and non-AIDS malignancies) and death • Smoking tobacco is independently associated with mortality and morbidity in HIV-positive patients • Despite this evidence rates of smoking remain high in HIV-positive patients
Background (2) • In HIV-negative smokers there is a substantial reduction in coronary heart disease within one to two years of stopping smoking • Clinical benefits from stopping smoking have not previously been reported in an HIV-positive population • If similar evidence could be found among HIVpositive smokers, this might provide further incentive for quitting Objective
• To estimate the rates of cardiovascular disease events and mortality after stopping smoking among patients in the D:A:D study
• The D:A:D study is a prospective, multi-national observational study formed by the collaboration of 11 cohorts of HIV-infected patients.
• 33,308 HIV-positive patients are followed in 212 clinics in Europe, the US and Australia
• Primary objective: to establish whether the use of cART is associated with an increased risk of CVD
• Secondary objectives: diabetes-mellitus, stroke and invasive cardiovascular procedures; non-AIDS cancers, renal failure and liver failure
• All D:A:D patients who report smoking status at baseline, and no prior CVD, were included
• Current (yes/no) and ever (yes/no) smoking status is collected at each visit • Duration of stopping smoking determined only for current smokers at baseline:
• Calculated from the mid-point between the last visit where patients reported being a current smoker to the first visit s/he reported being a non-smoker • Patients who reported that they re-started smoking were assumed to do so at the mid-point of the respective visits 
